An Inter‐Cooperative Biohybrid Platform to Enable Tumor Ablation and Immune Activation
Source abstract
Abstract
Abstract A biohybrid therapeutic system, consisting of responsive materials and living microorganisms with inter‐cooperative effects, is designed and investigated for tumor treatment. In this biohybrid system, S2O32−‐intercalated CoFe layered double hydroxides (LDH) are integrated at the surface of Baker's yeasts. Under the tumor microenvironment, functional interactions between yeast and LDH are effectively triggered, resulting in S2O32− release, H2S production, and in‐situ generation of highly catalytic agents. Meanwhile, the degradation of LDH in the tumor microenvironment induces the exposure of the surface antigen of yeast, leading to effective immune activation at the tumor site. By virtue of the inter‐cooperative phenomena, this biohybrid system exhibits significant efficacy in tumor ablation and strong inhibition of recurrence. This study has potentially offered an alternative concept by utilizing the metabolism of living microorganisms and materials in exploring effective tumor therapeutics.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Layered Double Hydroxides Synthesis and Applications · Advanced Photocatalysis Techniques · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Silicon and Advanced Semiconductor Materials School of Materials Science and Engineering Zhejiang University Hangzhou 310027 China
ZJU‐Hangzhou Global Science and Technology Innovation Center Zhejiang University Hangzhou 311215 China
Tea Research Institute College of Agriculture and Biotechnology Zhejiang University Hangzhou 310058 China
Funding
National Natural Science Foundation of China · China Postdoctoral Science Foundation
References (37)
Show source-provided references
1. 10.1016/j.biomaterials.2021.12112410.1016/j.biomaterials.2021.121124 ↗
2. 10.1002/adhm.20200089310.1002/adhm.202000893 ↗
3. 10.1039/D0CS00152J10.1039/D0CS00152J ↗
4. 10.1016/j.jconrel.2020.07.00910.1016/j.jconrel.2020.07.009 ↗
5. 10.1016/j.nantod.2021.10133110.1016/j.nantod.2021.101331 ↗
6. 10.1016/j.biomaterials.2019.11922610.1016/j.biomaterials.2019.119226 ↗
7. 10.1021/acsnano.8b0223510.1021/acsnano.8b02235 ↗
8. 10.1038/nnano.2016.13710.1038/nnano.2016.137 ↗
9. Huang X. H. · Adv. Sci. · 2021 · 8
10. 10.1002/anie.20200264910.1002/anie.202002649 ↗
11. 10.1021/acsnano.1c0612310.1021/acsnano.1c06123 ↗
12. 10.1039/D0CS01571G10.1039/D0CS01571G ↗
13. 10.3390/beverages204003010.3390/beverages2040030 ↗
14. 10.3389/fgene.2020.58471810.3389/fgene.2020.584718 ↗
15. 10.3389/fmicb.2020.0071810.3389/fmicb.2020.00718 ↗
16. 10.3201/eid2708.21001810.3201/eid2708.210018 ↗
17. 10.1093/femsyr/fox05810.1093/femsyr/fox058 ↗
18. 10.1097/00000542-198301000-0000310.1097/00000542-198301000-00003 ↗
19. 10.1016/S0021-9258(18)85681-210.1016/S0021-9258(18)85681-2 ↗
20. 10.1126/science.115758110.1126/science.1157581 ↗
21. 10.1126/sciadv.160262910.1126/sciadv.1602629 ↗
22. 10.1016/0141-0229(82)90116-810.1016/0141-0229(82)90116-8 ↗
23. 10.3109/1354750X.2012.71567210.3109/1354750X.2012.715672 ↗
24. 10.1155/2013/97291310.1155/2013/972913 ↗
25. Kuppusamy P. · Cancer Res. · 2002 · 62 · 307
26. 10.1002/adfm.20210326210.1002/adfm.202103262 ↗
27. 10.1007/s12274-017-1750-910.1007/s12274-017-1750-9 ↗
28. 10.1016/S0962-8924(98)01412-310.1016/S0962-8924(98)01412-3 ↗
29. 10.1016/j.biomaterials.2020.12025710.1016/j.biomaterials.2020.120257 ↗
30. 10.1016/j.cej.2020.12791810.1016/j.cej.2020.127918 ↗
31. 10.1016/j.bbagen.2012.10.01810.1016/j.bbagen.2012.10.018 ↗
32. 10.1016/j.biomaterials.2021.12108010.1016/j.biomaterials.2021.121080 ↗
33. 10.1016/j.jff.2017.07.06110.1016/j.jff.2017.07.061 ↗
34. Li X. Y. · Int. J. Oncol. · 2019 · 54 · 271
35. 10.1038/s41568-020-0273-y10.1038/s41568-020-0273-y ↗
36. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
37. 10.1126/science.aac425510.1126/science.aac4255 ↗